INTRODUCTION
Thyroid nodules are common and can be encountered in up to 60% of individuals aged >60 years by ultrasound, and in approximately 5% to 7% by palpation. [1] [2] [3] The incidence of cancer in these thyroid nodules remains low and the majority are benign. [4] [5] [6] An accurate distinction between benign and cancerous thyroid nodules is important to offer the most appropriate treatment to patients. Since its introduction in the United States in the 1980s, fine-needle aspiration (FNA) biopsy, which currently is performed in the majority of cases with ultrasound guidance, represents the most effective triage procedure to reliably distinguish benign from malignant thyroid nodules in approximately 60% to 80% of cases, 7, 8 whereas the remaining nodules are diagnosed as "indeterminate for malignancy" on FNA, mainly due to the lack of specific cytomorphologic features needed for a definitive diagnosis. 9 In the updated version of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), the indeterminate cytologic diagnoses based on cytologic features are categorized as either atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (TBSRTC category III), follicular or oncocytic (Hurthle cell) neoplasm/suspicious for a follicular or oncocytic (Hurthle cell) neoplasm (FN/SFN) (TBSRTC category IV), or suspicious for malignancy (TBSRTC category V). 9 TBSRTC categories III and IV are most common because each of these diagnoses is rendered in approximately 10% of all FNA biopsies. 7 Molecular testing of thyroid FNA specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. 8 With the advent of next-generation sequencing technology and the accelerated discovery of thyroid cancer markers, molecular testing for indeterminate thyroid nodules has become increasingly common and is widely used as an adjunct diagnostic tool for thyroid nodules diagnosed as indeterminate on FNA.
Cancer Cytopathology April 2019 a 56-gene panel launched in 2014 (ThyroSeq v2). 13, 14 The latter version of this test not only used DNA and RNA for detecting point mutations/indels and gene fusions found in approximately 90% of papillary carcinomas, 15 but also used a limited gene expression panel to monitor the cellularity and cell lineage of the tested samples. This allowed an overall high positive predictive value (PPV) and negative predictive value (NPV) for cancer detection in TBSRTC categories III and IV nodules and facilitated the detection of parathyroid nodules and medullary carcinomas. 14, 16 More recent advances in the genetic science related to the molecular mechanisms of less common types of thyroid cancer, and particularly Hurthle cell carcinomas, 17, 18 offered an opportunity for the even more comprehensive and accurate detection of all main types of thyroid cancer, which led to the creation of the latest version of the ThyroSeq test.
ThyroSeq v3 Genomic Classifier
The 20 This study initially recruited 782 patients with 1013 thyroid nodules at 9 institutions in the United States and 1 institution in Singapore. Samples were collected by either rinsing the residual material in the aspiration needle from all passes or by placing a dedicated pass into the collection tube containing nucleic acid preservative solution. Of all the samples, 257 met all study requirements, and were diagnosed as one of the indeterminate TBSRTC categories (ie, category III, IV, or V), had informative ThyroSeq results, and had a final surgical pathology diagnosis. Surgical pathology results were reviewed centrally by a panel of expert thyroid pathologists. However, by study design, cytology smears were not reviewed centrally so that the study represented the "real-world" experience of thyroid nodules diagnosed as indeterminate cytology being evaluated by this test. The study was doubleblinded: molecular testing personnel were blinded to all FNA and histopathology diagnoses, and both cytologists and pathologists were blinded to molecular testing results. In addition, pathologists were blinded to the diagnoses made by local and other panel pathologists. The discrepant cases were reviewed by the panel to arrive at a consensus diagnosis. There was no post-unblind sample exclusion in the current study. The primary outcome of the study was assessing the sensitivity, specificity, NPV, and PPV of the ThyroSeq v3 GC in predicting the histopathologic diagnosis of a benign nodule versus cancer/noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid nodules with TBSRTC category III (AUS/FLUS) and category IV (SFN/FN) cytology results. Although not classified as carcinoma, NIFTP is considered to be a precancer, borderline tumor that requires surgical excision, 21, 22 and therefore it was grouped with cancer for data analysis. The final study cohort included 154 thyroid nodules and 93 thyroid nodules diagnosed as AUS/FLUS and SFN/FN, respectively. As shown in Table 1 cancer/NIFTP, the test demonstrated a NPV of 97% among these samples. There were 5 false-negative test results in the entire study cohort, representing 4 papillary carcinomas and 1 minimally invasive follicular carcinoma (Table 2) . 20 All of the missed cancers were intrathyroidal, low-risk, and low-stage tumors with no vascular invasion, extrathyroidal extension, or other aggressive features. The frequency of a negative test result or "benign call rate" in the current study was 61% for thyroid FNA specimens diagnosed as AUS/FLUS and SFN/FN. A residual cancer risk in these test-negative nodules was 3%. According to the National Comprehensive Cancer Network guidelines, if molecular testing in combination with imaging and clinical information predicts a malignancy risk of ≤5%, which is comparable to the malignancy risk of benign FNA cytology, clinical management may include observation. 23 It is important to note that although the sensitivity and specificity are independent The secondary outcome of the current clinical validation study was to evaluate the prediction of cancer/ NIFTP by specific genetic alterations. The results of the study demonstrated that among 105 test-positive samples, the probability of a histological diagnosis of cancer/ NIFTP varied by 57% to 100% based on a specific group of genetic alterations (Table 3) . 20 The high-risk (TERT and TP53) and BRAF V600E -like mutations conferred a cancer probability of 100%. Furthermore, the BRAF V600E -like mutations were found to be strongly predictive of classic papillary carcinoma in these nodules. The RASlike mutations were associated with a 57% probability of cancer/NIFTP and were predictive of the follicular variant of papillary carcinoma. The finding of copy number alterations conferred a 59% probability of cancer/NIFTP, and this group was found to be enriched in Hurthle cell carcinomas. Finally, gene expression alterations were associated with a 75% probability of cancer; this finding was made among a heterogeneous pathology group that included, in addition to papillary carcinomas, nonfollicular thyroid cell tumors such as medullary carcinomas and metastatic/secondary tumors. The latter were reliably predicted by the classifier based on the expression pattern of cell lineage markers. A more granular prediction of cancer probability and tumor phenotype by specific genetic alterations may help to inform the more individualized management of patients with indeterminate cytology nodules.
Benign Call Rate and the Avoidance of Diagnostic Surgeries
The benign call rate is a valuable characteristic for "ruleout tests" that allows the estimation of the percentage of patients with indeterminate cytology nodules who can avoid undergoing diagnostic surgeries and be managed similarly to patients with benign cytology results. The study by Steward et al found a ThyroSeq V3 GC benign call rate of 61% of cases diagnosed as AUS/FLUS and SFN/FN, indicating that up to 61% of surgeries may be avoided for patients with these nodules. 20 This includes 82% of all histologically benign thyroid nodules with diagnoses of AUS/FLUS and SFN/FN. This study also compared the performance of ThyroSeq V3 Cancer Cytopathology April 2019 GC with that of another commonly used test for thyroid nodules, the Afirma GSC (Veracyte Inc, South San Francisco, California), as reported elsewhere. 25 Based on these 2 multicenter studies of approximately similar size, the benign call rate for the ThyroSeq V3 GC was 61% compared with a benign call rate of 54% for the Afirma GSC, with 82% of histologically benign thyroid nodules classified as negative by the ThyroSeq V3 GC compared with 68% by Afirma GSC (Table 4) . 20, 25 It is interesting to note that a recent study by Ohori et al evaluated the benign call rate of the ThyroSeq V3 GC during the routine clinical use of molecular testing at the University of Pittsburgh Medical Center. 26 This study included 224 consecutive cases with indeterminate cytology for which the benign call rate was 74%, which is even higher than that found in the multicenter study. Although the study was retrospective and represented a single institution, it provided evidence that the benign call rate of the ThyroSeq v3 GC found in the multi-institutional study 20 should be expected to be higher when the test is used routinely. Further studies are required to evaluate the "real-world" performance of this test in different clinical populations to fine-tune its application for the management of patients with thyroid nodules.
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